Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F22%3A00001204" target="_blank" >RIV/61383082:_____/22:00001204 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14160/22:00127365
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/36307183/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/36307183/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/ejhpharm-2022-003535" target="_blank" >10.1136/ejhpharm-2022-003535</a>
Alternative languages
Result language
angličtina
Original language name
Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection
Original language description
Abstract: Considering its very short elimination half-life, the approved oxacillin dosage might not be sufficient to maintain the pharmacokinetic/pharmacodynamics (PK/PD) target of time-dependent antibiotics. This study aimed to describe the population pharmacokinetics of oxacillin and to explore the probability of PK/PD target attainment by using various dosing regimens with oxacillin in staphylococcal infections. Both total and unbound oxacillin plasma concentrations retrieved as a part of routine therapeutic drug-monitoring practice were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were used to generate the theoretical distribution of unbound oxacillin plasma concentration–time profiles at various dosage regimens. Data from 24 patients treated with oxacillin for staphylococcal infection have been included into the analysis. The volume of distribution of oxacillin in the population was 11.2 L, while the elimination rate constant baseline of 0.73 h−1 increased by 0.3 h−1 with each 1 mL/s/1.73 m2 of the estimated glomerular filtration rate (eGFR). The median value of oxacillin binding to plasma proteins was 86%. The superiority of continuous infusion in achieving target PK/PD values was demonstrated and dosing according to eGFR was proposed. Daily oxacillin doses of 9.5 g, 11 g, or 12.5 g administered by continuous infusion have been shown to be optimal for achieving target PK/PD values in patients with moderate, mild, or normal renal function, respectively
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EUROPEAN JOURNAL OF HOSPITAL PHARMACY
ISSN
2047-9956
e-ISSN
—
Volume of the periodical
2022
Issue of the periodical within the volume
Oct
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
1-11
UT code for WoS article
000877092100001
EID of the result in the Scopus database
2-s2.0-85142782956